secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001628280-24-020454
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026
--------------------------------------------------------------------------------

- Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.
- Cash $206.7M as of Mar 31, 2024; expected cash runway into first half of 2026.
- FHD-286 combo in AML dose escalation ongoing; initial clinical data expected H2 2024.
- IND submitted for FHD-909 (first-in-class oral BRM selective inhibitor); Phase 1 in BRG1-mutated NSCLC expected H2 2024.
- Appointed Kristian Humer as CFO in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/fhtx-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer